CEO Presentation to 2025 Annual General Meeting
Filed with ASX · · 23 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallThis presentation includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied
In the deck
Story so far
Earlier from Mesoblast
- Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
- Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
- James M. O’Brien Appointed Chief Financial Officer at Mesoblast
- Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
- Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
Later from Mesoblast
- Ryoncil Revenue Growth Highlighted in AGM Trading Update
- Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
- Mesoblast Participation at Piper Sandler Conference
- Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
- Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast